WO1996018732A3 - Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides - Google Patents

Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides Download PDF

Info

Publication number
WO1996018732A3
WO1996018732A3 PCT/US1995/016368 US9516368W WO9618732A3 WO 1996018732 A3 WO1996018732 A3 WO 1996018732A3 US 9516368 W US9516368 W US 9516368W WO 9618732 A3 WO9618732 A3 WO 9618732A3
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
dna
replication
dna synthesis
triplex
Prior art date
Application number
PCT/US1995/016368
Other languages
French (fr)
Other versions
WO1996018732A9 (en
WO1996018732A2 (en
Inventor
Sergei M Mirkin
G M Samadashwily
Original Assignee
Univ Pennsylvania
Sergei M Mirkin
G M Samadashwily
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Sergei M Mirkin, G M Samadashwily filed Critical Univ Pennsylvania
Publication of WO1996018732A2 publication Critical patent/WO1996018732A2/en
Publication of WO1996018732A9 publication Critical patent/WO1996018732A9/en
Publication of WO1996018732A3 publication Critical patent/WO1996018732A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Specifically designed oligodeoxyribonucleotides form triplexes in single- or double-strand DNA at homopurine-homopyrimidine targets. These triplexes block in vitro DNA synthesis by all DNA polymerases studied, including Sequenase®, Taq, Vent, and Pol I. A similar phenomenon occurs when DNA polymerases are supplemented with accessory replication proteins, including SSB protein. Replication blockage is highly sequence-specific and even one or two point substitutions within either the target sequence or the oligonucleotide abolish the effect. Sequence-specific blocking of DNA replication in vivo is facilitated by the methods and compositions of the present invention.
PCT/US1995/016368 1994-12-15 1995-12-14 Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides WO1996018732A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35808994A 1994-12-15 1994-12-15
US08/358,089 1994-12-15

Publications (3)

Publication Number Publication Date
WO1996018732A2 WO1996018732A2 (en) 1996-06-20
WO1996018732A9 WO1996018732A9 (en) 1996-10-03
WO1996018732A3 true WO1996018732A3 (en) 1997-02-13

Family

ID=23408267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016368 WO1996018732A2 (en) 1994-12-15 1995-12-14 Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides

Country Status (1)

Country Link
WO (1) WO1996018732A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914137B2 (en) 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
JP4220744B2 (en) 2001-09-25 2009-02-04 株式会社アイシン・コスモス研究所 Processing libraries using ligation inhibition
US20060135455A1 (en) 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
CA2631677C (en) 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
WO2023187394A1 (en) * 2022-03-31 2023-10-05 The University Court Of The University Of Edinburgh Controllable gene expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007295A1 (en) * 1991-10-07 1993-04-15 The Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
WO1994017086A1 (en) * 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007295A1 (en) * 1991-10-07 1993-04-15 The Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
WO1994017086A1 (en) * 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CONFERENCE ON PHARMACEUTICAL DESIGN II: NUCLEIC ACID BINDING DRUGS; HELD FROM 31-01 TO 01-02-94 IN PALO ALTO, CA, USA *
DAYN, A. ET AL.: "Intramolecular DNA triplexes: unusual sequence requirements and influence on DNA polymerization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, December 1992 (1992-12-01), WASHINGTON US, pages 11406 - 11410, XP002007117 *
GIOVANNANGELI, C. ET AL.: "Oligonucleotide clamps arrest DNA synthesis on a single-stranded DNA target", PNAS 90 (01-11-93);10013-7, XP002007115 *
MIRKIN, S. & FRANK-KAMENETSKII, M.: "H-DNA and related structures", ANNU.REV.BIOPHYS.BIOMOL.STRUCT., vol. 23, 1994, pages 541 - 576, XP000574782 *
SAMADASHWILY, G. & MIRKIN, S.: "Trapping DNA polymerases using triplex-forming oligodeoxyribonucleotides", GENE 149 (4-11-94);127-36, XP002007113 *
SAMADASHWILY, G. ET AL.: "Suicidal nucleotide sequences for DNA polymerization", EMBO JOURNAL, vol. 12, 1993, EYNSHAM, OXFORD GB, pages 4975 - 4983, XP002007114 *
VO, T. ET AL.: "Targeting pyrimidine single strands by triplex formation: structural optimization of binding", NAR 23 (11-08-95);2937-44, XP002007116 *

Also Published As

Publication number Publication date
WO1996018732A2 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
WO2002006533A3 (en) Single primer pcr amplification of rna
WO2002018641A3 (en) Detection of cyp3a4 and cyp2c9 polymorphisms
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
WO2003064441A3 (en) Oligonucleotides comprising alternating segments and uses thereof
AU6589094A (en) 7-deazapurine modified oligonucleotides
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
EP0939621A4 (en) Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO2000023464A3 (en) Zinc finger binding domains for gnn
WO1997018334A3 (en) Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits
ATE467679T1 (en) OLIGOMERIC COMPOUNDS FOR MODULATING BCL-2
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2003091264A3 (en) Non nucleoside reverse transcriptase inhibitors
EP1165594A4 (en) Antisense oligonucleotide modulation of stat3 expression
WO2003031932A3 (en) Methods and compositions for detecting colon cancers
WO2000014217A3 (en) G-motif oligonucleotides and uses thereof
WO2003011117A3 (en) Methods and compositions for treating and preventing distal bowel lesions
EP1027877A4 (en) Tooth coating composition
EP1173614A4 (en) Antisense oligonucleotides comprising universal and/or degenerate bases
WO2004022770A3 (en) Compositions and methods for synthesizing nucleic acids
WO1996018732A3 (en) Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides
WO2003040397A3 (en) Asymmetric pcr with nuclease-free polymerase or nuclease-resistant molecular beacons
AU1062997A (en) Novel polymer supports for nucleic acid synthesis
Sasaki et al. Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA